Last reviewed · How we verify
NCT01296425: ECOS AUT
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Austria
trial testing Easypod™ in Growth Disorders in 50 participants. Completed in 31 December 2015.
31 December 2015
Quick facts
| Lead sponsor | Merck KGaA, Darmstadt, Germany |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 31 July 2011 |
| Primary completion | 31 December 2015 |
| Estimated completion | 31 December 2015 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Easypod™
Conditions studied
- Growth Disorders — all drugs for Growth Disorders →
Sponsor
Merck KGaA, Darmstadt, Germany — full company profile →
Who can join
Adults 2 to 18, any sex, with Growth Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a National, Multicentre, Observational Registry to study adherence and long term outcomes of therapy in paediatric subjects using Easypod™ electromechanical device for growth hormone treatment from hospitals in Austria and to assess the level of adherence of subjects receiving SAIZEN® via Easypod™.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01296425
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Easypod™
Trials testing the same drug.
- NCT01363674 — To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Greece · completed
- NCT01267526 — A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Pediatric Subje · completed
- NCT01291394 — To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France · completed
Other recruiting trials for Growth Disorders
Currently open trials in the same condition.
- NCT06662045 — Impact of Iron Deficiency Anemia on Neurobehavioral and Cognitive Development in Children Aged 6 to 24 Months · recruiting
- NCT06037473 — The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg · recruiting
- NCT05916144 — The Effect of Interaction-Based Early Education Program Applied to Grandparents on the Grandchildren's Health · NA · active not recruiting
- NCT05382637 — Growth Hormone in a Patient With a Dominant-Negative GHR Mutation · Phase 2 · active not recruiting
- NCT03761498 — Is There a Microbiome Associated With Poor Growth in Preterm Infants? · active not recruiting
Other Merck KGaA, Darmstadt, Germany trials
Trials by the same sponsor.
- NCT03845140 — L-PZQ ODT in Schistosoma Infected Children · Phase 3 · completed
- NCT03858049 — Efficacy and Safety of Crinone Versus Combination Medication (ACCESS) · Phase 4 · terminated
- NCT03745144 — Effects of Cladribine Tablets on the PK of Microgynon® · Phase 1 · completed
- NCT03717155 — Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC · Phase 2 · completed
- NCT03725072 — Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01296425 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Merck KGaA, Darmstadt, Germany
- Last refreshed: 26 December 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01296425.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing